{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T05:24:22Z","timestamp":1724995462327},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1245\/s10434-021-09902-2","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T21:02:34Z","timestamp":1618693354000},"page":"6024-6029","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor-Nipple Distance of \u2265\u20091\u00a0cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"28","author":[{"given":"Tracy-Ann","family":"Moo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Rossi","family":"Saccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate R.","family":"Pawloski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"D\u2019Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary C.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill S.","family":"Gluskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almir","family":"Bitencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audree","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virgilio","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"9938","key":"9902_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"6","key":"9902_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791\u2013800.","journal-title":"Lancet Oncol."},{"issue":"2","key":"9902_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1634\/theoncologist.2016-0268","volume":"22","author":"JC Singh","year":"2017","unstructured":"Singh JC, Mamtani A, Barrio A, et al. Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: a single center experience. Oncologist. 2017;22(2):139\u201343.","journal-title":"Oncologist."},{"issue":"10","key":"9902_CR4","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1245\/s10434-019-07560-z","volume":"26","author":"WA Young","year":"2019","unstructured":"Young WA, Degnim AC, Hoskin TL, et al. Outcomes of > 1300 nipple-sparing mastectomies with immediate reconstruction: the impact of expanding indications on complications. Ann Surg Oncol. 2019;26(10):3115\u201323.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"9902_CR5","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1245\/s10434-019-07418-4","volume":"26","author":"AJ Bartholomew","year":"2019","unstructured":"Bartholomew AJ, Dervishaj OA, Sosin M, et al. Neoadjuvant chemotherapy and nipple-sparing mastectomy: timing and postoperative complications. Ann Surg Oncol. 2019;26(9):2768\u201372.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"9902_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clbc.2017.08.010","volume":"18","author":"P Jadeja","year":"2018","unstructured":"Jadeja P, Ha R, Rohde C, et al. Expanding the criteria for nipple-sparing mastectomy in patients with poor prognostic features. Clin Breast Cancer. 2018;18(3):229\u201333.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"9902_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.breast.2015.08.001","volume":"24","author":"S Santoro","year":"2015","unstructured":"Santoro S, Loreti A, Cavaliere F, et al. Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy. Breast. 2015;24(5):661\u20136.","journal-title":"Breast"},{"issue":"10","key":"9902_CR8","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1245\/s10434-013-3152-x","volume":"20","author":"SB Coopey","year":"2013","unstructured":"Coopey SB, Tang R, Lei L, et al. Increasing eligibility for nipple-sparing mastectomy. Ann Surg Oncol. 2013;20(10):3218\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"9902_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1245\/s10434-019-07948-x","volume":"27","author":"MG Valero","year":"2020","unstructured":"Valero MG, Muhsen S, Moo TA, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: indications, complications, and oncologic outcomes. Ann Surg Oncol. 2020;27(2):344\u201351.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9902_CR10","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1245\/s10434-019-07554-x","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Chun YS, Sagara Y, Golshan M, Erdmann-Sager J. National patterns of breast reconstruction and nipple-sparing mastectomy for breast cancer, 2005\u20132015. Ann Surg Oncol. 2019;26(10):3194\u2013203.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"9902_CR11","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1245\/s10434-018-6759-0","volume":"25","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Morigi C, Bagnardi V, et al. Oncological outcomes of nipple-sparing mastectomy: a single-center experience of 1989 patients. Ann Surg Oncol. 2018;25(13):3849\u201357.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"9902_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.crad.2018.03.008","volume":"73","author":"G Mariscotti","year":"2018","unstructured":"Mariscotti G, Durando M, Houssami N, et al. Preoperative MRI evaluation of lesion-nipple distance in breast cancer patients: thresholds for predicting occult nipple-areola complex involvement. Clin Radiol. 2018;73(8):735\u201343.","journal-title":"Clin Radiol."},{"issue":"5","key":"9902_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/01.sap.0000216946.83252.e4","volume":"56","author":"AK Schecter","year":"2006","unstructured":"Schecter AK, Freeman MB, Giri D, Sabo E, Weinzweig J. Applicability of the nipple-areola complex-sparing mastectomy: a prediction model using mammography to estimate risk of nipple-areola complex involvement in breast cancer patients. Ann Plast Surg. 2006;56(5):498\u2013504 (discussion 504).","journal-title":"Ann Plast Surg."},{"issue":"8","key":"9902_CR14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1007\/s00268-016-3487-0","volume":"40","author":"JM Ryu","year":"2016","unstructured":"Ryu JM, Nam SJ, Kim SW, et al. Feasibility of nipple-sparing mastectomy with immediate breast reconstruction in breast cancer patients with tumor-nipple distance less than 2.0 cm. World J Surg. 2016;40(8):2028\u201335.","journal-title":"World J Surg."},{"issue":"4","key":"9902_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4048\/jbc.2019.22.e48","volume":"22","author":"E Alsharif","year":"2019","unstructured":"Alsharif E, Ryu JM, Choi HJ, et al. Oncologic outcomes of nipple-sparing mastectomy with immediate breast reconstruction in patients with tumor-nipple distance less than 2.0 cm. J Breast Cancer. 2019;22(4):613\u201323.","journal-title":"J Breast Cancer."},{"issue":"15","key":"9902_CR16","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ejca.2012.04.017","volume":"48","author":"M D'Alonzo","year":"2012","unstructured":"D\u2019Alonzo M, Martincich L, Biglia N, et al. Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. Eur J Cancer. 2012;48(15):2311\u20138.","journal-title":"Eur J Cancer"},{"key":"9902_CR17","doi-asserted-by":"publisher","first-page":"108754","DOI":"10.1016\/j.ejrad.2019.108754","volume":"122","author":"J Koh","year":"2020","unstructured":"Koh J, Park AY, Ko KH, Jung HK. MRI diagnostic features for predicting nipple-areolar-complex involvement in breast cancer. Eur J Radiol. 2020;122:108754.","journal-title":"Eur J Radiol."},{"issue":"14","key":"9902_CR18","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ejca.2015.07.001","volume":"51","author":"R Ponzone","year":"2015","unstructured":"Ponzone R, Maggiorotto F, Carabalona S, et al. MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. Eur J Cancer. 2015;51(14):1882\u20139.","journal-title":"Eur J Cancer."},{"issue":"30","key":"9902_CR19","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1200\/JCO.2008.20.8785","volume":"27","author":"EF Brachtel","year":"2009","unstructured":"Brachtel EF, Rusby JE, Michaelson JS, et al. Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol. 2009;27(30):4948\u201354.","journal-title":"J Clin Oncol."},{"issue":"6","key":"9902_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10434-999-0609-z","volume":"6","author":"C Laronga","year":"1999","unstructured":"Laronga C, Kemp B, Johnston D, Robb GL, Singletary SE. The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin-sparing mastectomy. Ann Surg Oncol. 1999;6(6):609\u201313.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"9902_CR21","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1245\/s10434-016-5366-1","volume":"23","author":"TA Moo","year":"2016","unstructured":"Moo TA, Pinchinat T, Mays S, et al. Oncologic outcomes after nipple-sparing mastectomy. Ann Surg Oncol. 2016;23(10):3221\u20135.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09902-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09902-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09902-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T01:07:33Z","timestamp":1632445653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09902-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9902"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09902-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth Morris reports grants from the National Institutes of Health\/National Cancer Institute, during the conduct of the study; and grants from Grail, Inc. outside the submitted work. Monica Morrow has received honoraria from Genomic Health. Tracy-Ann Moo, Carolina Rossi Saccarelli, Elizabeth J. Sutton, Varadan Sevilimedu, Kate R. Pawloski, Timothy M. D\u2019Alfonso, Mary C. Hughes, Jill S. Gluskin, Almir Bitencourt, Audree Tadros, Mary L. Gemignani, and Virgilio Sacchini have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}